E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/19/2006 in the Prospect News Biotech Daily.

Forest at sector perform rating by RBC

RBC Capital Markets analyst Douglas Miehm rated Forest Laboratories Inc. at sector perform, above average risk, on news that the company's earnings per share of $0.62 beat the analyst's estimate of $0.53 and consensus of $0.52. Revenues were $816.3 million, up from $711.8 million last year, and ahead of RBC's forecast of $792.0 million and consensus of $786.1 million. RBC raised its price target to $48. Shares of the New York City-based pharmaceutical company were up 33 cents, or 0.78%, at $42.90 on volume of 3,622,900 shares versus the three-month running average of 2,162,210 shares. (NYSE: FRX)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.